Studies have revealed that mTOR was activated in pancreatic cancer tissues, and mTOR inhibitors are currently applied in molecular-targeted cancer therapies in clinical treatment (Vignot et al. 2005; Kagawa 2012). The gene discussed is MTOR; the disease is familial pancreatic carcinoma.